Why I’m Fighting for This
My name is Catherine Cooke. I’m 53, a mother, a friend, and a trusted business advisor to Kiwi business owners. On 6 November 2024, a routine mammogram led to a diagnosis of triple negative breast cancer (TNBC)—a rare, aggressive cancer. Overnight, I was not only fighting for my life, but also against a funding system that denies early-stage TNBC patients access to Keytruda.
Keytruda significantly reduces recurrence and improves survival. Yet in New Zealand, it remains unfunded for early-stage TNBC. Patients like me are left to either take on $85,000–$110,000 in debt or go without. For many, this is emotionally and financially devastating.
Pharmac’s own advisors recommended funding in 2023, and global trials confirmed its life-saving impact in 2024. Still, no decision has been made. Meanwhile, we risk progressing to incurable cancer.
This is about more than me. It's about:
✅ Preventing higher healthcare costs from late-stage cancer
✅ Reducing pressure on mental health and welfare systems
✅ Keeping patients in the workforce
✅ Combating misinformation—early-stage TNBC is not funded
We call on Parliament to:
-Fund Keytruda for early-stage TNBC immediately
-Include it in standard treatment guidelines
-Clarify that current funding only covers advanced TNBC
Help us turn this fight for survival into a fight for equity. On behalf of 17,096 New Zealanders—I am pushing this petition presented to parliament by Nancy Lu, MP on my behalf.